XIMINO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XIMINO (XIMINO).
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
| Metabolism | Hepatic metabolism is minimal; primarily excreted unchanged in urine and feces. Not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4. |
| Half-life | Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (range 0.6-1.0 L/kg), indicating extensive tissue distribution and penetration into extravascular spaces. |
| Bioavailability | Oral: 60% (range 50-70%) due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes to peak plasma concentration; therapeutic effect onset: 1-2 hours. Intravenous: within 5-10 minutes. |
| Duration of Action | 12-24 hours depending on dose and renal function; clinical effect persists for 24 hours after single dose. |
| Molecular Weight | 413.45 |
400 mg orally twice daily with food for 7 days.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl ≥30 mL/min: No adjustment. CrCl 15-29 mL/min: 200 mg orally twice daily. CrCl <15 mL/min or hemodialysis: 200 mg orally once daily. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use with caution; maximum dose 200 mg twice daily. Child-Pugh C: Not recommended. |
| Pediatric use | ≥12 years (≥45 kg): 400 mg orally twice daily with food for 7 days. <12 years: Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider age-related decline in CrCl. |
| 1st trimester | Contraindicated due to teratogenic effects (neural tube defects, cardiovascular malformations). |
| 2nd trimester | Contraindicated due to risk of fetal growth retardation and oligohydramnios. |
| 3rd trimester | Contraindicated due to risk of premature ductus arteriosus closure and persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for XIMINO (XIMINO).
| Placental transfer | Crosses placenta readily; fetal concentrations 50-100% of maternal serum levels. |
| Breastfeeding | Excreted in human milk; potential for serious adverse effects in nursing infants including kernicterus and sulfonamide displacement of bilirubin. Discontinue breastfeeding or avoid drug. |
| Lactation Rating |
■ FDA Black Box Warning
Not approved for use in patients with severe hepatic impairment; hepatotoxicity has been reported. Fatalities have occurred with hepatic injury. Discontinue if liver injury occurs.
| Serious Effects |
Hypersensitivity to XIMINO or any sulfonamidePorphyriaSevere hepatic impairmentSevere renal impairment (CrCl <15 mL/min)Pregnancy (especially 1st and 3rd trimesters)BreastfeedingInfants <2 months of age (except for congenital toxoplasmosis)
| Precautions | Hepatotoxicity: discontinue if signs of liver injury appear., Photosensitivity: avoid excessive sunlight or UV light., Use caution in patients with renal impairment; dose adjustment may be needed., May cause dizziness or blurred vision; avoid driving if affected., Pregnancy category D; avoid use during pregnancy due to risk of fetal harm., Pseudoaneurysm formation has been reported in patients with Marfan syndrome. |
| Food/Dietary | Avoid dairy products (milk, cheese, yogurt) within 1-2 hours of taking XIMINO, as calcium can chelate the drug and reduce absorption. Also avoid iron supplements, antacids containing aluminum, calcium, or magnesium, and multivitamins containing minerals within 2-4 hours of dosing. Food in general, particularly high-fat meals, may delay absorption; take on an empty stomach if possible. Alcohol can increase the risk of hepatotoxicity and should be limited or avoided. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | XIMINO (xenomycophenolic acid) is contraindicated in pregnancy. First trimester exposure is associated with craniofacial malformations (cleft lip/palate), microtia, and cardiovascular defects in up to 45% of cases. Second and third trimester exposure may lead to intrauterine growth restriction, oligohydramnios, and preterm birth. Use adequate contraception before, during, and 6 weeks after therapy. |
| Fetal Monitoring | Monitor complete blood count (CBC), liver function tests (LFTs), and renal function monthly. During pregnancy, perform targeted fetal ultrasound for craniofacial and cardiac anomalies at 18-22 weeks. Measure amniotic fluid index if oligohydramnios suspected. Monitor neonatal CBC and infection signs for 2 weeks postpartum. |
| Fertility Effects | Based on animal studies, XIMINO may impair female fertility by disrupting ovarian cycle and embryo implantation. Male fertility may be reduced due to effects on spermatogenesis. Reversibility of these effects after cessation is unknown. |
| Clinical Pearls | XIMINO (minocycline hydrochloride extended-release) has high lipophilicity, leading to excellent tissue penetration, including into the sebaceous glands and central nervous system. It is associated with a lower incidence of vestibular side effects compared to immediate-release minocycline. Monitor for skin hyperpigmentation, especially in scars and sun-exposed areas, which can occur months after initiation. Avoid use in patients with a history of hepatitis or recent use of hepatotoxic drugs. Use with caution in patients with autoimmune disorders due to risk of drug-induced lupus. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily, with a full glass of water. · Do not take with food, especially dairy products, as they can decrease absorption. Take at least 1 hour before or 2 hours after meals. · Complete the full course of therapy even if your symptoms improve to prevent antibiotic resistance. · This medication may cause dizziness, lightheadedness, or blurred vision; avoid driving or operating machinery until you know how it affects you. · Report any signs of severe headache, visual changes, or skin rash to your healthcare provider immediately. · Avoid prolonged sun exposure and use sunscreen; this medication can cause photosensitivity. · Notify your doctor if you become pregnant or plan to become pregnant; this medication can harm an unborn baby. |